NCI-2024-06506

Beamion LUNG-2 A Phase III, open-label, randomized, activecontrolled, multi-centre trial evaluating orally administered zongertinib (BI 1810631) compared with standard of care as firstline treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations

This Phase III research study is investigating a new oral drug, zongertinib, compared to standard care as a first-line treatment for patients with advanced non-squamous non-small cell lung cancer that has specific HER2 mutations. These mutations are known to drive cancer growth and are therefore targets for specific therapies. The trial aims to determine if zongertinib is more effective and/or has fewer side effects than the current standard treatment for this particular type of lung cancer.

Phase 3: A phase 3 clinical trial is a large-scale study designed to assess the effectiveness and safety of a new medical treatment or approach compared to a standard treatment

non-small cell lung cancer (NSCLC): A type of lung cancer with non small cells that grow too much and can spread to other parts of the body

advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06151574

Clinical Trial Site: Einstein

To see all available clinical trials click here.